Blue Earth Diagnostics and Sinotau Pharmaceutical have have formed a partnership in China involving Blue Earth's flotufolastat F-18 PET radiotracer..
The companies said they will now work to develop the radiotracer and commercialize it after obtaining the necessary approvals. The deal "has the potential to fill a significant gap in the Chinese domestic market where there are currently no [F-18 labeled prostate-specific membrane antigen]-PET diagnostic radiopharmaceuticals available," Blue Earth said.
The radiotracer, known in the U.S. market under the brand name Posluma, received U.S. Food and Drug Administration clearance in May of this year.
